Effect of plasma-derived or recombinant factor VIII on inhibitor development. A systematic review

被引：0

|

作者：

Iorio, A.

Halimeh, S.

Bidlingmaier, C.

Ettingshausen, C. E.

Gringeri, A.

Holzhauer, S.

Knoefler, R.

Kreuz, W.

Kurnik, K.

Manner, D.

Santagostino, E.

Mannucci, P. M.

Nowak-Goettl, U.

机构：

来源：

HAEMOPHILIA | 2010年 / 16卷 / 02期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

收藏

页码：410 / 410

页数：1

相关论文

共 50 条

[31] Rates of Inhibitor Development in Previously Untreated Patients with Severe Hemophilia A Treated with Plasma-Derived or Recombinant Factor VIII: No Proof of Difference or Proof of No Difference?
Messori, Andrea
Fadda, Valeria
Maratea, Dario
Trippoli, Sabrina
SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2014, 40 (02): : 269 - 270
[32] RECOMBINANT AND PLASMA-DERIVED FACTOR-VIIA DO NOT CORRECT BLEEDING-TIME IN A RABBIT FACTOR-VIII INHIBITOR MODEL
TURECEK, PL
SCHWARZ, HP
THROMBOSIS AND HAEMOSTASIS, 1995, 73 (06) : 986 - 986
[33] Trial Results Reveal Greater Risk of Inhibitor Formation in Patients With Hemophilia A Receiving Recombinant Factor VIII Than in Patients Receiving Plasma-Derived Factor VIII
不详
AMERICAN JOURNAL OF MANAGED CARE, 2016, 22 : 20 - 21
[34] The increased demand for plasma-derived factor VIII in Italy
Arcieri, Romano
Calizzani, Gabriele
Candura, Fabio
Mannucci, Pier Mannuccio
BLOOD TRANSFUSION, 2017, 15 (03) : 279 - 280
[35] Continuous factor VIII infusion therapy in patients with haemophilia A undergoing surgical procedures with plasma-derived or recombinant factor VIII concentrates
Dingli, D
Gastineau, DA
Gilchrist, GS
Nichols, WL
Wilke, JL
HAEMOPHILIA, 2002, 8 (05) : 629 - 634
[36] Multicenter comparison of inhibitor (Inh) development on plasma-derived (PD) vs recombinant (rec) factor VIII(fVIII) in severe hemophilia a patients (sHA pts).
DiMichele, D
Rothschild, C
Sultan, Y
Kroner, B
Aledort, L
BLOOD, 1999, 94 (10) : 238A - 238A
[37] Response to "Rates of Inhibitor Development in Previously Untreated Patients with Severe Hemophilia A Treated with Plasma-Derived or Recombinant Factor VIII: No Proof of Difference or Proof of No Difference?"
Franchini, Massimo
Mengoli, Carlo
SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2014, 40 (02): : 271 - 272
[38] Plasma-derived or recombinant factor VIII products and inhibitors in previously untreated patients with severe hemophilia
van der Bom, Johanna G.
Gouw, Samantha C.
van den Berg, H. Marijke
BLOOD, 2007, 110 (03) : 1074 - 1075
[39] Lower inhibitor risk of plasma-derived factor VIII concentrates versus recombinant factor VIII concentrates in patients with severe haemophilia A : result from SIPPET study and comments
Biron-Andreani, Christine
Diaz, Isabelle
Navarro, Robert
Schved, Jean-Francois
HEMATOLOGIE, 2019, 25 (02): : 93 - 99
[40] A Systematic Review of Efficacy and Safety of Plasma-Derived von Willebrand Factor/Factor VIII Concentrate (Voncento) in von Willebrand Disease
Rugeri, Lucia
Thomas, Will
Schirner, Kathrin
Heyder, Lisa
Auerswald, Guenter
THROMBOSIS AND HAEMOSTASIS, 2024, 124 (09) : 828 - 841

← 1 2 3 4 5 →